Navigation Links
Certain Breast Cancer Drugs Linked With Heart Risks in Older Women
Date:12/9/2010

By Kathleen Doheny
HealthDay Reporter

THURSDAY, Dec. 9 (HealthDay News) -- Long-term use of aromatase inhibitors, drugs often prescribed to breast cancer patients, may increase the risk of heart problems for postmenopausal women, according to a Canadian researcher.

''There have always been suspicions," said Dr. Eitan Amir, senior fellow at Princess Margaret Hospital in Toronto, who is scheduled to present the findings this week at the San Antonio Breast Cancer Symposium in Texas.

In December 2008, the U.S. Food and Drug Administration added a warning label to anastrozole, an aromatase inhibitor marketed as Arimidex, citing a potential increased risk for heart disease.

Amir's team evaluated previously published studies to find out if other aromatase inhibitors also increased the risk of heart disease in postmenopausal women with breast cancer. ''We looked at seven trials which have compared aromatase inhibitors with tamoxifen,'' he said

Aromatase inhibitors, which also include Femara and Aromasin, prevent the production of estrogen, which some cancers need to grow and spread. Tamoxifen, another drug frequently prescribed for breast cancer patients with estrogen-sensitive tumors, blocks the effect of estrogen in breast tissue. Under current guidelines, the two drugs may be used in either order for the several years of treatment typically recommended.

''Overall, there is a 26 percent increased risk in heart events -- heart attack, angina and heart failure -- for women taking aromatase inhibitors for longer duration," which typically means more than three years, Amir said.

''But those are relative statistics, and they can be a bit misleading," he says. A relative risk compares the risk in two different groups of people. Another measure -- absolute risk -- refers to one person's actual risk of developing the disease over a given time period.

In this study, the absolute risk to any one woman taking an aromatase inhibitor was less alarming. "Only 1 percent more got heart disease," Amir said. But the risk among those who already had risk factors for heart disease, such as high blood pressure, was as high as 7 percent.

''Aromatase inhibitors are being given routinely to many [breast cancer] patients," he said. And not everyone gets the same benefit, he said, so treatment should be based not just on breast cancer risk, but on the patient's cardiovascular profile and other health risks, he said.

"If you have heart disease, perhaps you want to avoid aromatase inhibitors," Amir said.

Another option would be to switch from one drug to the other, to avoid staying on aromatase inhibitors long-term, he said.

When he compared women who used aromatase inhibitors first to those who used tamoxifen first, the risk for serious adverse effects was similar. But there was a hint that switching drugs reduced the risk of death from other causes.

Because this study was presented at a medical meeting, the findings should be viewed as preliminary until they are published in a peer-reviewed journal.

Still, the findings are no surprise, said Dr. Julie Gralow, director of breast medical oncology at Seattle Cancer Care Alliance, who reviewed the study results but was not involved in it.

Aromatase inhibitors aren't perfect, she said. Neither is tamoxifen, which has been linked with blood clots, stroke and cataracts.

"For some women maybe tamoxifen is better," said Gralow, who is careful to follow her patients closely and monitor them for any suggestion of heart disease.

As with much of medical practice, decisions must be made on a case-by-case basis, she said.

More information

To learn more about aromatase inhibitors, visit the U.S. National Cancer Institute.

SOURCES: Eitan Amir, M.D., senior fellow, Princess Margaret Hospital, Toronto, Ontario, Canada; Julie Gralow, M.D., director of breast medical oncology and Seattle Cancer Alliance, and professor, oncology division, University of Washington, Seattle, Wash.; San Antonio Breast Cancer Symposium, Dec. 8-12, 2010, San Antonio, Texas


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Certain Formulations of Omega-3s Might Help With Depression
2. Diagnosis uncertainty increases anxiety in patients
3. Women Taking Certain Epilepsy Drugs Can Safely Breast-Feed, Study Suggests
4. Low Vitamin D Linked to Deterioration in Certain Leukemia Patients
5. New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients
6. New Drug Shows Promise Against Certain Lung Cancers
7. Certain cancer therapies success depends on presence of immune cell, Stanford study shows in mice
8. Certain new therapies for age-related eye disease do not appear to increase heart risks
9. A revolutionary new way of reversing certain cancers
10. Bacteria identified that may lead to inflammatory bowel disease in certain individuals
11. Double-Dose Plavix Benefits Certain Patients, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Certain Breast Cancer Drugs Linked With Heart Risks in Older Women
(Date:5/25/2016)... ... , ... "FCPX LUT Intense allows users to cycle through different high-contrast color ... of Pixel Film Studios. , With the FCPX LUT Intense Plugin ... their footage. A LUT is a Lookup Table that contains a mathematical formula for ...
(Date:5/25/2016)... ... ... Consumer access to organic foods and grower access to food processers is about ... and other plant-based foods, will introduce the first consumer product (a new breakfast cereal) ... Organic Products. , The transitional designation means the cereal was made using at least ...
(Date:5/25/2016)... ... 25, 2016 , ... Stern Environmental Group , of Secaucus, New Jersey, ... as Stern’s Real Time Monitoring (RTM) Device. Stern Environmental Group will sell ... industry, colleges for use in dormitories, shelters, and nursing homes for real time bedbug ...
(Date:5/24/2016)... ... May 24, 2016 , ... Sterling Global Products is ... unique and patented refillable hanging wipe dispenser. The campaign kick-off video is located via ... end June 25, 2016. The goal is to raise $1,000 per day for a ...
(Date:5/24/2016)... ... ... To better understand the impact of lung cancer in women, the American Lung ... Today, the Lung Association announced Sharad Goyal, MD , as the recipient of The ... Lung Association’s LUNG FORCE initiative, which raises awareness of the impact of lung cancer ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... -- Experts from various countries ... role of technology in innovative healthcare ... International Conference of VPS-Penn Medicine opened in Abu ... Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Culture and ... provide personalized medicine and tailor-made healthcare in disease treatment and ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
(Date:5/20/2016)... , May 20, 2016 According ... driver is the increasing demand for affordable healthcare solutions as ... steadily on the rise. In countries like the US, the ... In the US, the consumer price index inflation rate stood ... inflation rate moved up to 3.62% during the same time ...
Breaking Medicine Technology: